The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. DanCann Pharma AS's Revenue for the
three
months ended in Sep. 2025 was $0.25 Mil. DanCann Pharma AS's average Accounts Receivable for the
three
months ended in Sep. 2025 was $0.10 Mil.
Hence, DanCann Pharma AS's Receivables Turnover for the
three
months ended in Sep. 2025 was 2.62.
DanCann Pharma AS (GREY:DCPXF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
DanCann Pharma AS Receivables Turnover Related Terms
DanCann Pharma AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for DanCann Pharma AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCPXF vs ZTS, UTHR, RGC: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DanCann Pharma AS Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where DanCann Pharma AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DanCann Pharma AS (DCPXF) has a Receivables Turnover of 2.62 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's Receivables Turnover too high?
DanCann Pharma AS's current Receivables Turnover is 2.62. The Drug Manufacturers industry median Receivables Turnover is 5.07. DanCann Pharma AS's value of 2.62 is 48.3% below this industry median. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Receivables Turnover compare to ZTS and UTHR?
DanCann Pharma AS's Receivables Turnover of 2.62 can be compared against companies in the Drug Manufacturers industry. The industry median Receivables Turnover is 5.07. DanCann Pharma AS's value of 2.62 is 48.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DanCann Pharma AS's current Receivables Turnover of 2.62 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DanCann Pharma AS and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current Receivables Turnover is 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Receivables Turnover of 2.62. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Receivables Turnover is 2.62 and 48.3% below the Drug Manufacturers industry median of 5.07. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Receivables Turnover is 2.62 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DanCann Pharma AS (DCPXF) Overvalued in 2026?
Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued.
The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.
Key valuation signals for DCPXF:
Receivables Turnover: 2.62
GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
Industry Position: 48.3% below the Drug Manufacturers median
No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score
Get the complete analysis for DCPXF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCPXF has been successfully added to your 
